2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.25 Tupper

PP01.25 Tupper - Poster

Pdf Summary

A retrospective multi-center study was conducted on patients aged 18-89 diagnosed with non-small cell lung cancer (NSCLC) between 2013-2020. The study focused on biomarker testing receipt within 6 months of diagnosis, analyzing factors like sociodemographic, cancer characteristics, testing completion, and results. The study found that biomarker testing was performed in 38.8% of patients, with higher rates among Asian, non-smoking, stage III/IV, and non-squamous patients. Most testing yielded valid results ranging from 77-92%. The prevalence of targetable mutations varied by race/ethnicity, smoking status, cancer stage, and histology. EGFR mutations were most prevalent in Asian patients (52.2%), while less-tested mutations like MET and ERBB2 were observed in Black patients. Specifically, BRAF and MET mutations were more common in patients with a smoking history, with EGFR mutations present in 14.3% of patients with a smoking history. The study highlighted the need for stronger recommendations for biomarker testing in a broader population to improve mortality rates. In conclusion, the data indicated a significant burden of targetable mutations in certain groups and emphasized the importance of early and equitable biomarker testing for improved targeted therapy in NSCLC patients.

Keywords

multi-center study

non-small cell lung cancer

biomarker testing

sociodemographic factors

cancer characteristics

testing completion

targetable mutations

EGFR mutations

MET mutations

ERBB2 mutations